Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
23,597,628
-
Total 13F shares
-
1,063,685
-
Share change
-
+40,465
-
Total reported value
-
$3,241,840
-
Price per share
-
$3.05
-
Number of holders
-
19
-
Value change
-
+$183,775
-
Number of buys
-
10
-
Number of sells
-
4
Institutional Holders of Rein Therapeutics, Inc. - Common Stock, $0.001 par value (RNTX) as of Q4 2023
As of 31 Dec 2023,
Rein Therapeutics, Inc. - Common Stock, $0.001 par value (RNTX) was held by
19 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,063,685 shares.
The largest 10 holders included
Alerce Investment Management, L.P., GEODE CAPITAL MANAGEMENT, LLC, VANGUARD GROUP INC, GAGNON SECURITIES LLC, BLAIR WILLIAM & CO/IL, RENAISSANCE TECHNOLOGIES LLC, Sigma Planning Corp, Texas Capital Bank Wealth Management Services Inc, Tower Research Capital LLC (TRC), and UBS Group AG.
This page lists
19
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.